Bayer Initiates P-III Study of Aflibercept for the Prevention of Blindness in Premature Infants with Retinopathy of Prematurity

Bayer Initiates P-III Study of Aflibercept for the Prevention of Blindness in Premature Infants with Retinopathy of Prematurity

Shots:

  • The P-III study will assess the efficacy, safety and tolerability of Aflibercept (intravitreal) in ~100 infants with ROP across 34 countries
  • Bayer & Regeneron collaborated to develop aflibercept whereas Regeneron holds exclusive rights to aflibercept in the US while Bayer retained exclusive marketing rights outside the US with equal profit sharing (Ex-Japan)
  • Aflibercept (marketed as Eylea) is an anti-VEGF therapy approved in ~100 countries for 5 indications including patients with wAMD, macula edema following retinal vein occlusion, diabetic macular edema and myopic choroidal neovascularization

Click here to read full press release/ article | Ref: Bayer | Image: All Work